← Pulse/Companies

PureTech on Pulse

Biotech

The full thread of our PureTech coverage — a running record of every development we've tracked, with the VC take on each.

2
Stories
2
With a headline figure
Jul 2, 2026
Date

Coverage Timeline

newest first
  1. FUNDINGCelea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug→
  2. FUNDINGCelea Therapeutics Raises $180M to Push Lung Drug Into Phase 3→

All Coverage

FUNDING$180M Series B

Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug

Celea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.

Jul 2, 2026
FUNDING$180 million

Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3

PureTech-founded Celea Therapeutics raised $180 million to fund a head-to-head Phase 3 trial testing its drug deupirfenidone against the current standard of care for idiopathic pulmonary fibrosis.

Jul 2, 2026